# A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC)

Source: https://onco.cc/trials/nct07465757/  
OnCo record `nct07465757` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Paclitaxel / nab-paclitaxel in small-cell lung cancer, run by Puma Biotechnology, Inc., now recruiting.

## Summary

A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) is a phase 2 interventional study registered as NCT07465757 by Puma Biotechnology, Inc., with 50 participants planned, started 2026-09-30 and due to reach its primary completion in 2028-03-31. Interventions recorded: Alisertib, Alisertib, Alisertib, Alisertib, Alisertib. Conditions listed: Small Cell Lung Cancer ( SCLC ). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07465757
- Phase: 2
- Setting: A Phase 2 Study of Alisertib in Combination With Paclitaxel in Patients With Small Cell Lung Cancer
- Sponsor: Puma Biotechnology, Inc.
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT07465757: https://clinicaltrials.gov/study/NCT07465757

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Alisertib](https://onco.cc/drugs/alisertib/), [Paclitaxel / nab-paclitaxel](https://onco.cc/drugs/paclitaxel/)
- companies: [Puma Biotechnology](https://onco.cc/companies/puma-biotechnology/)

---
JSON: https://onco.cc/api/v1/entities/nct07465757.json